Sumitomo Dainippon confirms takeover talks with Cynata

19 July 2019

Australian stem cell and regenerative medicine firm Cynata Therapeutics (ASX: CYP) saw its shares leap as much as 15.5% to A$1.85, after it revealed that it has received an indicative, non-binding and conditional proposal from Japan’s Sumitomo Dainippon Pharma (TYO: 4506) regarding a possible acquisition at a price of $2.00 cash per share – around $202 million in total - by way of a scheme of arrangement.

The release advises that the Cynata board has decided to grant non-exclusive due diligence access to Sumitomo Dainippon Pharma.

It also stated that Cynata has continued engagement with certain other parties in relation to making a proposal. Cynata’s discussions with such other parties have ceased.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK